These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
814 related articles for article (PubMed ID: 23494461)
1. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis. Yang ZY; Wu XY; Huang YF; Di MY; Zheng DY; Chen JZ; Ding H; Mao C; Tang JL Int J Cancer; 2013 Oct; 133(8):1914-25. PubMed ID: 23494461 [TBL] [Abstract][Full Text] [Related]
2. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267 [TBL] [Abstract][Full Text] [Related]
3. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Mao C; Yang ZY; Hu XF; Chen Q; Tang JL Ann Oncol; 2012 Jun; 23(6):1518-25. PubMed ID: 22039088 [TBL] [Abstract][Full Text] [Related]
5. A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. Kawazoe A; Shitara K; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Fuse N; Yamanaka T; Doi T; Ohtsu A; Yoshino T BMC Cancer; 2015 Apr; 15():258. PubMed ID: 25886136 [TBL] [Abstract][Full Text] [Related]
6. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Molinari F; Felicioni L; Buscarino M; De Dosso S; Buttitta F; Malatesta S; Movilia A; Luoni M; Boldorini R; Alabiso O; Girlando S; Soini B; Spitale A; Di Nicolantonio F; Saletti P; Crippa S; Mazzucchelli L; Marchetti A; Bardelli A; Frattini M Clin Cancer Res; 2011 Jul; 17(14):4901-14. PubMed ID: 21632860 [TBL] [Abstract][Full Text] [Related]
7. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. Sood A; McClain D; Maitra R; Basu-Mallick A; Seetharam R; Kaubisch A; Rajdev L; Mariadason JM; Tanaka K; Goel S Clin Colorectal Cancer; 2012 Jun; 11(2):143-50. PubMed ID: 22285706 [TBL] [Abstract][Full Text] [Related]
8. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299 [TBL] [Abstract][Full Text] [Related]
9. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Lu X; Li Y; Li Y; Zhang X; Shi J; Feng H; Yu Z; Gao Y BMC Cancer; 2023 Nov; 23(1):1117. PubMed ID: 37974093 [TBL] [Abstract][Full Text] [Related]
10. Loss of PTEN expression as a predictor of resistance to anti-EGFR monoclonal therapy in metastatic colorectal cancer: evidence from retrospective studies. Wang ZH; Gao QY; Fang JY Cancer Chemother Pharmacol; 2012 Jun; 69(6):1647-55. PubMed ID: 22610356 [TBL] [Abstract][Full Text] [Related]
11. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431 [TBL] [Abstract][Full Text] [Related]
12. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520 [TBL] [Abstract][Full Text] [Related]
13. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer. Soeda H; Shimodaira H; Watanabe M; Suzuki T; Gamoh M; Mori T; Komine K; Iwama N; Kato S; Ishioka C Int J Clin Oncol; 2013 Aug; 18(4):670-7. PubMed ID: 22638623 [TBL] [Abstract][Full Text] [Related]
14. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? Inno A; Di Salvatore M; Cenci T; Martini M; Orlandi A; Strippoli A; Ferrara AM; Bagalà C; Cassano A; Larocca LM; Barone C Clin Colorectal Cancer; 2011 Dec; 10(4):325-32. PubMed ID: 21729677 [TBL] [Abstract][Full Text] [Related]
15. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. De Roock W; Claes B; Bernasconi D; De Schutter J; Biesmans B; Fountzilas G; Kalogeras KT; Kotoula V; Papamichael D; Laurent-Puig P; Penault-Llorca F; Rougier P; Vincenzi B; Santini D; Tonini G; Cappuzzo F; Frattini M; Molinari F; Saletti P; De Dosso S; Martini M; Bardelli A; Siena S; Sartore-Bianchi A; Tabernero J; Macarulla T; Di Fiore F; Gangloff AO; Ciardiello F; Pfeiffer P; Qvortrup C; Hansen TP; Van Cutsem E; Piessevaux H; Lambrechts D; Delorenzi M; Tejpar S Lancet Oncol; 2010 Aug; 11(8):753-62. PubMed ID: 20619739 [TBL] [Abstract][Full Text] [Related]
16. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. Laurent-Puig P; Cayre A; Manceau G; Buc E; Bachet JB; Lecomte T; Rougier P; Lievre A; Landi B; Boige V; Ducreux M; Ychou M; Bibeau F; Bouché O; Reid J; Stone S; Penault-Llorca F J Clin Oncol; 2009 Dec; 27(35):5924-30. PubMed ID: 19884556 [TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy. Llovet P; Sastre J; Ortega JS; Bando I; Ferrer M; García-Alfonso P; Donnay O; Carrato A; Jiménez A; Aranda E; León A; Grávalos C; Cámara JC; Feliú J; Sanchíz B; Caldés T; Díaz-Rubio E Mol Diagn Ther; 2015 Dec; 19(6):397-408. PubMed ID: 26341080 [TBL] [Abstract][Full Text] [Related]
18. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Sartore-Bianchi A; Martini M; Molinari F; Veronese S; Nichelatti M; Artale S; Di Nicolantonio F; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A Cancer Res; 2009 Mar; 69(5):1851-7. PubMed ID: 19223544 [TBL] [Abstract][Full Text] [Related]
19. PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis. Wu S; Gan Y; Wang X; Liu J; Li M; Tang Y J Cancer Res Clin Oncol; 2013 May; 139(5):891-900. PubMed ID: 23435830 [TBL] [Abstract][Full Text] [Related]
20. Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis. Song QB; Wang Q; Hu WG World J Gastroenterol; 2015 Apr; 21(14):4365-72. PubMed ID: 25892888 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]